The management of stroke patients by neurologists: Common questions and new observations

Seminars in Neurology

Volumn 22, Issue 1, 2002, Pages 53-61

  Lopez Yunez, Alfredo M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute stroke therapy; Secondary stroke prevention; Thrombolytic therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CLOPIDOGREL; CYANOCOBALAMIN; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; FOLIC ACID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PERINDOPRIL; PROUROKINASE; PYRIDOXINE; RAMIPRIL; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ANGIOPLASTY; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STENT; STROKE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036074627     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-33048     Document Type: Review

References (43)

1. Tissue plasminogen activator for acute ischemic stroke
2. European Stroke Prevention Study 2. Dipyridamole and acetylsalycilic acid in the secondary prevention of stroke
3. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
4. Prevention of first stroke. A review of guidelines and multidisciplinary consensus statement from the National Stroke Association
5. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
6. Improving delivery of acute stroke therapy: The TLL Temple Foundation Stroke Project
7. Protocol violations are associated with increased risk of ICH in community-based rt-PA use
8. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study
9. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000
10. Early stroke treatment associated with better outcomes: The NINDS rt-PA stroke study
11. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke
12. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke
13. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz trans-cranial Doppler monitoring
14. Intra-arterial pro-urokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in acute cerebral thromboembolism
15. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: The PROACT II trial
16. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke
17. Intra-arterial thrombolysis in acute basilar artery thromboembolism: The initial Mayo Clinic experience
18. Long-term follow-up of patients after intraarterial thrombolytic therapy of acute vertebrobasilar artery occlusion
19. Stroke thrombolytic therapy of acute basilar artery occlusion: Variables affecting recanalization and outcome
20. Basilar artery occlusion: Clinical and radiological correlation
21. Safety of intra-arterial thrombolysis in the postoperative period
22. Endovascular administration after intravenous infusion of thrombolytic agents for the treatment of patients with acute ischemic strokes
23. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke
24. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial
25. Fraxiparin in ischemic stroke study
26. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
27. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients
28. Cerebrovascular disease and statins: A potential addition to the therapeutic armamentarium for stroke prevention
29. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization
30. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease
31. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke
32. Stroke recurrence in patients with patent foramen ovale: The Lausanne Study
33. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both
34. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis
35. Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: A stopped trial
36. Carotid endarterectomy vs. stent: A randomized trial
37. Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: A 5-year prospective analysis
38. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): A randomised trial
39. Carotid angioplasty and stenting versus carotid endarterectomy: Randomized trial in a community hospital
40. A therapeutic window for carotid endarterectomy in patients with asymptomatic carotid stenosis
41. Endarterectomy for asymptomatic carotid artery stenosis
42. New imaging strategies for patient selection for thrombolytic and neuroprotective therapies